Publications and media
Cardiac Interventions Today, July 14, 2021
atHeart Medical’s reSept ASD Occluder Studied in ASCENT ASD United States Pivotal Trial
Read more...
BioWorld MedTech, April 22, 2021
Annette Boyle: atHeart Medical begins IDE trial for septal closure device
Read more...
Diagnostic and Interventional Cardiology, April 20, 2021
Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial
Read more...
Cardiac Interventions Today, April 20, 2021
atHeart Medical Commences Operations and Prepares Pivotal Trial of reSept ASD Occluder
Read more...
March 1, 2021
reSept ASD Occluder by atHeart Medical: atHeart Medical aims to establish the first and only transcatheter ASD occluder with a metal-free frame as a new standard of care for atrial septal defects (ASDs).
Read more...
CONTACT
CARAG AG Bahnhofstrasse 9 6340 Baar Switzerland
T +41 41 766 02 02 F +41 41 766 02 00 info@carag.com